<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04348708</url>
  </required_header>
  <id_info>
    <org_study_id>HMI-102-102</org_study_id>
    <nct_id>NCT04348708</nct_id>
  </id_info>
  <brief_title>Long-Term Follow Up Study of Subjects Previously Administered HMI 102</brief_title>
  <official_title>An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects With PAH Deficiency Previously Administered HMI 102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Homology Medicines, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Homology Medicines, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH
      Deficiency Previously Administered HMI 102
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH
      Deficiency Previously Administered HMI 102. Subjects will have already received a single dose
      of HMI-102 administered intravenously
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Anticipated">August 30, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events of special interest (AESIs) and serious adverse events (SAEs) related to HMI 102</measure>
    <time_frame>Baseline to year 5</time_frame>
    <description>Subjects with at least one AESI or SAE</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Phe Concentration</measure>
    <time_frame>Baseline to year 5</time_frame>
    <description>Plasma phenylalanine (Phe) concentration at each time point during the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phe-restricted diet</measure>
    <time_frame>Baseline to year 5</time_frame>
    <description>Incidence of subjects with a Phe-restricted diet</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenylketonuria Quality of Life Questionnaire (PKU-QOL</measure>
    <time_frame>Baseline to year 5</time_frame>
    <description>Quality of life (QOL), as assessed using the Phenylketonuria-QOL (PKU-QOL) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein intake</measure>
    <time_frame>Baseline to year 5</time_frame>
    <description>Protein intake relative to Phe concentration at each time point during the study</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">21</enrollment>
  <condition>Phenylketonuria</condition>
  <condition>PAH Deficiency</condition>
  <arm_group>
    <arm_group_label>Dose Level Cohort 1</arm_group_label>
    <description>Dose Level 1 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Cohort 2</arm_group_label>
    <description>Dose Level 2 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level Cohort 3</arm_group_label>
    <description>Dose Level 3 of HMI-102 delivered intravenously one time</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>HMI-102</intervention_name>
    <description>HMI-102 is an AAVHSC15 vector containing a functional copy of the human PAH gene</description>
    <arm_group_label>Dose Level Cohort 1</arm_group_label>
    <arm_group_label>Dose Level Cohort 2</arm_group_label>
    <arm_group_label>Dose Level Cohort 3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Neutralizing AAV antibody, AAV antibody (IgG), Anti-PAH antibody, Vector DNA in blood, Vector
      DNA in body fluids, Serum Chemistry, Hematology
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with PAH Deficiency who were previously administered HMI-102
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject was previously administered HMI 102.

          -  Subject is able to understand the purpose and risks of the study and is willing to
             provide informed consent.

          -  Subject is able to comply with all study procedures and long-term follow-up.

        Exclusion Criteria:

          -  Participation in the study is not in the subject's best interest, in the opinion of
             the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Boston Children's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 13, 2020</study_first_submitted>
  <study_first_submitted_qc>April 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PKU</keyword>
  <keyword>Phenylketonuria</keyword>
  <keyword>PAH Deficiency</keyword>
  <keyword>Phenylalanine</keyword>
  <keyword>Adeno Associated Virus</keyword>
  <keyword>AAVHSC15</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

